

Ajanta House Charkop, Kandivli West, Mumbai 400 067 India T +91 22 6606 1000 F +91 22 6606 1200 E legal.info@ajantapharma.com W www.ajantapharma.com

24th July 2023

Scrip Code: BSE – AJANTPHARM 532331	Scrip Code: NSE AJANTPHARM EQ
Phiroze Jeejeebhoy Towers Dalal Street,	National Stock Exchange of India, Exchange Plaza, 5 th Floor, Plot no. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051
BSE LIMITED	National Stock Exchange of India.

Ref.: Intimation under Regulations 29(1)(e) of the Listing Regulations

Subject: Notice of the meeting of Board of Directors to consider dividend on equity shares of the company

Dear Sirs/Madam,

This is with reference to our letter dated 14th July 2023, informing you about the Board meeting scheduled on Thursday, 27th July 2023 to *inter-alia* consider and take on record the unaudited financial results for the first quarter ended 30th June 2023.

Pursuant to Regulation 29(1)(e) of Listing Regulations, we hereby inform you that, at the aforesaid Board Meeting, the Board of Directors will also consider proposal for:

- a. declaration of interim dividend, if any, for the financial year ending 31st March 2024; and
- b. fixation of Friday, 4th August 2023 as the Record Date for the payment of interim dividend, if declared.

You are requested to please take a note of the same and disseminate to all concerned.

Thanking you,

Yours faithfully,

Gaurang Shah

VP – Legal & Company Secretary